(Información remitida por la empresa firmante)
H2 2023 Long-term follow-up (Kidney tx): 5-year data readoutH2 2023 Sarepta DMD pre-treatment Phase 1b: Commence clinical study
H2 2023 HNSA-5487 (Lead NiceR candidate): Completion of Phase 1 study
2024 U.S. ConfIdeS (Kidney tx): Phase 3: BLA submission
2024 GBS Phase 2: Outcome of the comparative efficacy analysis to IGOS data
2024 Genethon Crigler-Najjar Phase 1/2: Initiate clinical study with imlifidase prior to GNT-0003
Updated financial calendar 2023/2024
October 18, 2023 Interim Report for January – September 2023
February 2, 2024 Full-year Report for January – December 2023
March 20, 2024 Annual Report 2023
April 17, 2024 Interim Report January – March 2024
July 17, 2024 Half-year Report January – June 2024
October 23, 2024 Interim Report for January – September 2024
Conference call details
Hansa Biopharma will host a telephone conference today Thursday July 20, 2023, 14:00 CET / 8:00am EST.
The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, CCO and U.S. President, Matthew Shaulis and CFO, Donato Spota. The presentation will be held in English.
Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call.
To participate in the telephone conference, please use the dial-in details provided below:
Sweden: +46 10 884 80 16
United Kingdom: +44 20 3936 2999
United States: +1 646 664 1960
Participant access code: 323180
The webcast will be available on https://events.q4inc.com/attendee/206699686
The interim report and latest investor presentation can be downloaded from our web:
Interim report January to June 2023https://www.hansabiopharma.com/investors/financial-reports/
Investor road show presentation Q2, 2023 https://www.hansabiopharma.com/investors/presentations/
This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.
For further information, please contact:
Klaus Sindahl, VP Head of Investor Relations
M: +46 (0) 709–298 269
E: klaus.sindahl@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802
E: stephanie.kenney@hansabiopharma.com
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-half-year-report-2023-301881780.html